8-K filing — OS Therapies Inc (OSTX)
Filed: 2026-08-21 AccNo: 0001213900-26-092651 Size: 603 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
FDA Grants OS Therapies’ Requested Type C Statistical Methods Meeting To Review 2.5-Yr Overall Survival Data From Phase 2b Trial Of OST-HER2 In Prevention Of Recurrence In Pulmonary Metastatic Osteosarcoma; Meeting To Occur In Mid-September
Meeting to occur in mid-September 2026Interim 3-year Overall Survival data expected early September, 2026Decisions on appropriate comparator arm to interpret OST-HER2 clinical efficacy, RMAT designation and Rolling
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 12:48 PM
- Checked
- Aug 13, 2026, 12:49 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
OS Therapies Enters Open Market Sale Agreement With Jefferies; May Offer Common Stock Up To $75M Through Jefferies
-SEC Filing
Read original at benzingaOS Therapies Terminates At Market Issuance Sales Agreement On July 23; Co. Announces Termination Of Sales Agreement Effective July 28
Read original at benzinga